Aboul-Fettouh Nader, Morse Daniel, Patel Jigar, Migden Michael R
Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dermatol Pract Concept. 2021 Oct 1;11(Suppl 2):e2021169S. doi: 10.5826/dpc.11S2a169S. eCollection 2021 Nov.
Cutaneous squamous cell carcinomas (cSCC) represent one of the most diagnosed non-melanoma skin cancers and its incidence is increasing globally. Whereas early stage and low risk cSCC is typically treated with surgery, and in some cases other localized therapeutic modalities, locally advanced or metastatic cSCC is a cause of significant morbidity and mortality that requires a different approach to therapy. Therapeutic attempts at treating advanced cSCC include a multi-disciplinary approach with considerations for surgery, radiation, and systemic therapies. In this review, we will discuss the various systemic therapies that have been trialed for advanced cSCC, beginning with the early cytotoxic and platinum-based agents as well as their corresponding limitations. We will then review the targeted approaches using EGFR inhibitors prior to discussing the more recent immunotherapeutics that have shown good tumor responses in this often-lethal disease.
皮肤鳞状细胞癌(cSCC)是最常被诊断出的非黑色素瘤皮肤癌之一,其全球发病率正在上升。早期和低风险的cSCC通常采用手术治疗,在某些情况下采用其他局部治疗方式,而局部晚期或转移性cSCC会导致严重的发病率和死亡率,需要采用不同的治疗方法。治疗晚期cSCC的尝试包括多学科方法,考虑手术、放疗和全身治疗。在本综述中,我们将讨论已针对晚期cSCC进行试验的各种全身治疗方法,首先是早期的细胞毒性和铂类药物及其相应的局限性。然后,在讨论最近在这种常致命疾病中显示出良好肿瘤反应的免疫疗法之前,我们将回顾使用表皮生长因子受体(EGFR)抑制剂的靶向治疗方法。